Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Scrip Intelligence, a leading source of news and strategic analysis for the global pharmaceutical industry, publish article about Isofol Medical

John Davis, journalist and editor for more than 30 years, of Scrip Intelligence recently interviewed Anders Rabbe, CEO of Isofol Medical AB, regarding the fundamental strategy behind the company’s recent IPO and important lessons learned from that process. The article has been made available and can be read via the link below: http://media.isofol.se/2017/07/ExecutiveInterviewScrip.pdf  Scrip intelligence – Pharmaceutical and biotech intelligence division of Informa Scrip intelligence is a leading source of news and strategic analysis for the global pharmaceutical industry,

Lindab International AB (publ): Lindab's Report for the Second Quarter 2017

Second Quarter 2017 · Net sales increased by 5 percent to SEK 2,118 m (2,016), of which organic growth amounted to 2 percent. · Adjusted[1)] operating profit increased by 9 percent to SEK 151 m (139). Operating profit increased to SEK 151 m (138). · Adjusted[1)] operating margin increased to 7.1 percent (6.9). · Profit for the period increased by 23 percent to SEK 106 m (86). · Earnings per share increased to SEK 1.39 (1.13). · Cash flow from operating activities amounted to SEK 162 m (187). · The net debt/equity ratio amounted to 0.4 (0.5) at the end of

Interim Report January-June 2017: Execution of the strategy and transformation to meet the challenge of digitization is on schedule

APRIL-JUNE 2017 · Net sales SEK 9,083m (9,590).  · Operating income SEK -291m (-270). · Adjusted operating income SEK -4m (-1). · Items affecting comparability, net, SEK -287m (-269). · Net income for the period SEK -336m (-282). · Earnings per share, SEK -0.17 (-0.14). · Cash flow from operating activities SEK 922m (364). JANUARY-JUNE 2017 · Net sales SEK 18,431m (19,228). · Operating income SEK -197m (30).  · Adjusted operating income SEK 188m (299). · Items affecting comparability, net, SEK -386m (-269). · Net income for the period SEK -320m (-

Read original

Episurf Medical has become an approved supplier to Spire Healthcare, one of the UK’s largest independent hospital providers

Episurf Medical (NASDAQ: EPIS B) has become an approved supplier to Spire Healthcare, one of the UK’s largest independent hospital providers with 39 hospitals, 10 clinics and two specialist cancer care centres across England, Wales and Scotland. The decision has been made following a review process.  “We are very pleased that, with the support from some of the UK’s leading surgeons, Episealer® has received approval from Spire Healthcare as a new treatment method for focal cartilage and bone damages of the knee”, says Pål Ryfors, CEO Episurf Medical. “Spire Healthcare delivers a very high

Combitech’s half-year report for January-June 2017

The technical consultancy company Combitech, an independent subsidiary of the defence and security company Saab AB, is releasing its interim report today for January-June 2017. The report shows continued increases both in sales and earnings.Summary of highlights during the second quarter of 2017:    · The annual digitalisation event Techxperience Day was held on 2 May, and attracted a large number of decision-makers in the industry. This year’s theme was innovation, security and autonomy, and the participants also emphasised the importance of collaboration between different

Camurus and Braeburn Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder

–      If approved, CAM2038 would provide weekly and monthly dosing options for patients with Opioid Use Disorder –      Priority Review of the NDA has been applied for which, if granted, would shorten the review process of CAM2038  –      Robust clinical dossier supports potential for novel subcutaneous buprenorphine depotsLund, Sweden and Princeton, N.J. — July 20, 2017 — Camurus (NASDAQ STO: CAMX) and Braeburn Pharmaceuticals (“Braeburn”) today announced the completion of the rolling submission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the

Invitation to telephone conference for half year report 2017

Mekonomen’s half year report for 2017 will be published on Friday, 28 July, at 07:30 a.m CET.  A telephone conference will be held at 09:00 a.m in English. Mekonomen's CEO Pehr Oscarson and interim CFO Karl Lindström will present the results and respond to questions at this English speaking conference. The presentation material will be available from 8:00 a.m CET on 28 July at www.mekonomen.com under the heading Investors/IR Presentations.  To participate in the English speaking conference,

DDM Holding AG and DDM Debt AB to report second quarter and half year 2017

DDM Holding AG (First North: DDM) and its subsidiary DDM Debt AB (Nasdaq Stockholm: DDM2), will publish their Q2 and half year 2017 interim reports on Thursday 3 August 2017, at 08:00 a.m. CET.Mr. Gustav Hultgren, CEO, and Mr. Fredrik Olsson, CFO, will host a conference call the same day, beginning at 10:00 a.m. CET, to present and comment on the DDM Group’s financial results. The conference will be held in English and can be followed live on www.ddm-group.ch  or by telephone with dial-in numbers: Sweden: +46 8 566 426 95 Switzerland:

DDM Holding AG and DDM Debt AB to report second quarter and half year 2017

DDM Holding AG (First North: DDM) and its subsidiary DDM Debt AB (Nasdaq Stockholm: DDM2), will publish their Q2 and half year 2017 interim reports on Thursday 3 August 2017, at 08:00 a.m. CET.Mr. Gustav Hultgren, CEO, and Mr. Fredrik Olsson, CFO, will host a conference call the same day, beginning at 10:00 a.m. CET, to present and comment on the DDM Group’s financial results. The conference will be held in English and can be followed live on www.ddm-group.ch  or by telephone with dial-in numbers: Sweden: +46 8 566 426 95 Switzerland:

YIT to start apartment sales in four significant apartment building projects in Finland and CEE countries worth approximately EUR 60 million in total

YIT Corporation Investor News July 20, 2017 at 9:00 a.m.YIT starts the apartment sales in four significant projects that YIT started to construct in the second quarter of the year. The projects support YIT’s growth strategy in Finland and in the CEE countries. Tampereen Ykköspurje project is constructed in the Keulakortteli city block, located in the new Ranta-Tampella living area in Tampere, Finland. The project comprises 35 apartments and the value of the project is approximately EUR 20 million. The project is completed in the fourth quarter of 2018. The fourth phase of Suomi

Finnair Group Half-Year Report 1 January–30 June 2017

Finnair’s earnings growth continues: all-time high profit for Q2 April–June 2017 · Revenue increased by 11.2% year-on-year to 633.4 million euros (569.6)*. · Available seat kilometres (ASK) grew by 6.8%. · Comparable operating result was 37.5 million euros (3.2). · Operating result was 89.1 million euros (0.2) including i.a. sales gain on an A350 aircraft. · Comparable EBITDAR** was 103.2 million euros (56.3). · Net cash flow from operating activities amounted to 162.2 million euros (119.6), and net cash flow from investing activities to -136.5 million euros (-149.0).*

Caverion Corporation’s Half Yearly Report for January 1 – June 30, 2017

Caverion Corporation Half Yearly Report July 20, 2017 at 9.00 a.m. EESTCaverion Corporation’s Half Yearly Report for January 1 – June 30, 2017  Turnaround progressing – Completion of a few older projects hurting profitability and cash flow April 1 – June 30, 2017  · Order backlog: EUR 1,512.7 (3/2017: 1,543.5) million. · Revenue: EUR 565.1 (615.5) million. · EBITDA excluding restructuring costs: EUR -6.0 (-6.8) million, or -1.1 (-1.1) percent of revenue. · EBITDA: EUR -13.0 (-14.4) million, or -2.3 (-2.3) percent of revenue. · Working capital: EUR 31.0 (15.3) million.

Interim report, January – June 2017: Growth continues on a really strong market

”Ework’s operations continued to grow in the second quarter, on what is still a very strong market. Progress in the quarter is in line with our budgeted, aggressive plan towards our long-term financial targets.”Extract from CEO Zoran Covic’s commentary to the Interim report.Second quarter 2017 compared to 2016  -       Net sales increased by 23% to SEK 2 389 M (1 934). -       EBIT for the period vas SEK 24,9 M (24,9). -       Order intake rose by 7% to SEK 3 248 M (3 022). -       Earnings after tax per share after dilution were SEK 1,12 (1,13). -       The consulting

Proact Board makes decision on buyback of own shares

The Board of Directors at Proact IT Group AB ("Proact") has made a decision to initiate buyback of its own shares within the scope of the authorisation concerning the acquisition of own shares, amounting to a maximum of 10 per cent of the shares, as obtained at the Annual General Meeting held on 9 May 2017. This authorisation may be exercised up to the time of the next Annual General Meeting. The purpose of buybacks is in accordance with the decision of the Annual General Meeting. The company’s own shares will be bought back in batches, depending on market conditions and applicable rules.

Hansa Medical Interim report April-June 2017

April – June 2017 in brief›› Continued patient enrolment in two ongoing Phase II studies with lead candidate IdeS in highly sensitized patients in the US and Europe. The objective is to have all 40 patients recruited and treated in the two separate studies by the end of 2017. All treated patients will be monitored for six months post treatment. ›› First patient treated in Phase II study with IdeS for acute renal failure in anti-GBM antibody disease. Approximately 15 patients will be recruited in this investigator initiated study at up to 15 clinics in Europe. The primary objective of

Evolution Gaming: Interim report January-June 2017

Second quarter of 2017 (Q2 2016) · Operating revenues increased by 56% to EUR 42.3 million (27.1) · EBITDA increased by 81% to EUR 19.2 million (10.6), corresponding to a margin of 45% (39) · Profit for the period amounted to EUR 14.6 million (7.6) · Earnings per share amounted to EUR 0.41 (0.21) The first half of 2017 (1H 2016) · Operating revenues increased by 58% to EUR 82.0 million (51.9) · EBITDA increased by 74% to EUR 36.3 million (20.9), corresponding to a margin of 44% (40) · Profit for the period amounted to EUR 27.4 million (15.3) · Earnings per

Fortum's Half-Year Financial Report 2017: Strategy implementation proceeds through Hafslund ownership restructuring. Low hydro volumes continue to...

FORTUM CORPORATION HALF-YEAR FINANCIAL REPORT JANUARY-JUNE 2017 20 JULY 2017 AT 9:00 EESTFortum's Half-Year Financial Report 2017: Strategy implementation proceeds through Hafslund ownership restructuring. Low hydro volumes continue to impact results April−June 2017  · Comparable EBITDA EUR 219 (209) million, +5% · Comparable operating profit EUR 109 (122) million, -11% · Operating profit EUR 66 (67) million, of which EUR -42 (-54) million related to items affecting comparability · Earnings per share EUR -0.08 (0.06), of which EUR -0.14 (0.00) related to a Swedish income

Enzymatica AB: Continued sales growth and breakthrough order from STADA

Interim report forEnzymatica AB (publ)JANUARY- JUNE 2017                                                                                                                                                                                                                                                                                                      Continued sales growth and breakthrough order from STADA Q2              · Net sales reached SEK 5.9 (4.9) million. · Loss after tax came in at SEK -10.8 (-12.8) million. · Earnings per share were SEK -0.12 (-0.20). ·

Momentum Group AB (publ): Interim Report - 3 months 1 April-30 June 2017

· Revenue increased by 1 percent to MSEK 1,400 (1,382). · Operating profit amounted to MSEK 42 (53). Adjusted operating profit (excluding items affecting comparability) totalled MSEK 52 (53), corresponding to an adjusted operating margin of 3.7 percent (3.8). · The return on working capital (P/WC) for the most recent 12-month period was 20 percent (22). · Net profit amounted to MSEK 31 (40). · Earnings per share totalled SEK 1.10 (1.40). · The operational net loan liability amounted to MSEK 281 (236) and the equity/assets ratio at the end of the reporting period was 41

Nordic Capital divests fast-growing payments company Bambora to global payments leader Ingenico Group

Nordic Capital Fund VIII (“Nordic Capital”) has signed an agreement to divest global payment company Bambora to Ingenico Group (publ.) for an Enterprise Value of approximately EUR 1.5 billion. Less than three years after its start-up, Bambora is now an industry innovator with a unique and compelling position in the global payments industry. Ingenico Group is one of the world’s largest payment companies and the acquisition of Bambora strengthens its online positioning and growth profile with its global omni-channel payments solutions. Nordic Capital and the management team in Bambora have

Boliden’s second quarter: High mined production and strong cash flow

Boliden’s second quarter was characterised by high mined production and strong cash flow. Revenue amounted to SEK 11,554 m (9,596) and the operating profit excluding revaluation of process inventory increased to SEK 2,196 m (901). Free cash flow amounted to SEK 2,152 m.“A quarter of high mined production and good production at copper smelters resulted in a cash flow of over SEK 2 billion. Production in Aitik and the Boliden Area has developed in a particularly positive manner. The high production compensated for maintenance shutdowns and deteriorated market terms compared to previous

Thule Group CEO and President Magnus Welander comments on the second quarter, April-June, 2017

Strong sales and high profitabilitySuccessful product launches and continued wins with retailers enabled us to deliver a strong result for the second quarter of 2017. Thanks to sales growth of 9 percent (after currency adjustment), combined with a highly cost-efficient organization, we achieved 24.2 percent EBIT-margin during the second quarter.The improved profitability was achieved despite rising costs for raw materials and ambitious investments in product development in our newer product categories.Following the divestment of our Specialty segment during the quarter, we are now a

BE Group Q2 2017 – Continued and stable underlying operating result

· Net sales increased by 10 percent to SEK 1,147 M (1,047), and by 15 percent excluding operations under restructuring. · The underlying operating result was at the same level as last year at SEK 21 M (21), despite fewer trading days. · The quarter was affected by non-recurring items of SEK -42 M related to the closure of the operations in Eskilstuna, the write-down of goodwill in Lecor and the reversal of part of the write-down of the participation in the joint venture ArcelorMittal BE Group SSC AB. · The operating result amounted to SEK -13 M (31). · The result after tax was

Interim report April - June 2017

"Continued good market trend" “During the second quarter of the year, sales increased by 26 percent, of which acquired units contributed 20 percentage points. Organic sales rose 3 percent. Excluding project businesses, comprising mainly offshore oil & gas-related operations – which are currently experiencing a difficult market situation – organic sales rose 5 percent, driven by improved demand in most market segments and in all geographic regions. General industry continued to develop well in all regions, and continued highly favorable organic trend was noted in Asia. Demand for our

There are no items matching the current filter
There are no more items matching the current filter
Back to top